- call +1-201-465-4211
- email sales@mrinsights.biz
Hereditary angioedema is a rare disease and is mostly mistaken for common allergic reactions and abdominal pain. This mainly on account of the lack of knowledge among both physicians and patients about the condition. About 40% of the affected patients are diagnosed correctly with hereditary angioedema in the US and Europe. With progress in diagnostic field and different initiatives undertaken by patient bodies and industry players to spread awareness, the market for hereditary angioedema is projected to grow.
Scope of the Report:
This report focuses on the Hereditary Angioedema in global market, especially in North America, Europe and Asia-Pacific, South America, Middle East and Africa. This report categorizes the market based on manufacturers, regions, type and application.
The worldwide market for Hereditary Angioedema is expected to grow at a CAGR of roughly xx% over the next five years, will reach xx million US$ in 2023, from xx million US$ in 2017, according to a new GIR (Global Info Research) study.
Market Segment by Manufacturers, this report covers
Pharming Group NV
Shire plc
CSL Limited
iBio Inc.
BioCryst Pharmaceuticals, Inc.
Ionis Pharmaceuticals, Inc.
Market Segment by Regions, regional analysis covers
North America (United States, Canada and Mexico)
Europe (Germany, France, UK, Russia and Italy)
Asia-Pacific (China, Japan, Korea, India and Southeast Asia)
South America (Brazil, Argentina, Colombia etc.)
Middle East and Africa (Saudi Arabia, UAE, Egypt, Nigeria and South Africa)
Market Segment by Type, covers
C1 Esterase Inhibitor
Kallikrein Inhibitor
Selective Bradykinin B2 Receptor Antagonist
Market Segment by Applications, can be divided into
Retail Pharmacies
Hospital Pharmacies
Online Pharmacies
There are 15 Chapters to deeply display the global Hereditary Angioedema market.
Chapter 1, to describe Hereditary Angioedema Introduction, product scope, market overview, market opportunities, market risk, market driving force;
Chapter 2, to analyze the top manufacturers of Hereditary Angioedema, with sales, revenue, and price of Hereditary Angioedema, in 2016 and 2017;
Chapter 3, to display the competitive situation among the top manufacturers, with sales, revenue and market share in 2016 and 2017;
Chapter 4, to show the global market by regions, with sales, revenue and market share of Hereditary Angioedema, for each region, from 2013 to 2018;
Chapter 5, 6, 7, 8 and 9, to analyze the market by countries, by type, by application and by manufacturers, with sales, revenue and market share by key countries in these regions;
Chapter 10 and 11, to show the market by type and application, with sales market share and growth rate by type, application, from 2013 to 2018;
Chapter 12, Hereditary Angioedema market forecast, by regions, type and application, with sales and revenue, from 2018 to 2023;
Chapter 13, 14 and 15, to describe Hereditary Angioedema sales channel, distributors, traders, dealers, Research Findings and Conclusion, appendix and data source
The base year for the study has been considered 2019, historic year 2014 and 2018, the forecast period considered is from 2020 to 2027. The regions analyzed for the market include North America, Europe, South America, Asia Pacific, and Middle East and Africa. These regions are further analyzed at the country-level. The study also includes attractiveness analysis of type, application and regions which are benchmarked based on their market size, growth rate and attractiveness in terms of present and future opportunity for understanding the future growth of the market.
Market is segmented on the basis:
The report offers in-depth analysis of driving factors, opportunities, restraints, and challenges for gaining the key insight of the market. The report emphasizes on all the key trends that play a vital role in the enlargement of the market from 2019 to 2026.
The report provides company profile of the key players operating in the market and a comparative analysis based on their business overviews industry offering, segment market share, regional presence, business strategies, innovations, mergers & acquisitions, recent developments, joint venture, collaborations, partnerships, SWOT analysis, and key financial information.
Table of Contents
1 Market Overview
1.1 Hereditary Angioedema Introduction
1.2 Market Analysis by Type
1.2.1 C1 Esterase Inhibitor
1.2.2 Kallikrein Inhibitor
1.2.3 Selective Bradykinin B2 Receptor Antagonist
1.3 Market Analysis by Applications
1.3.1 Retail Pharmacies
1.3.2 Hospital Pharmacies
1.3.3 Online Pharmacies
1.4 Market Analysis by Regions
1.4.1 North America (United States, Canada and Mexico)
1.4.1.1 United States Market States and Outlook (2013-2023)
1.4.1.2 Canada Market States and Outlook (2013-2023)
1.4.1.3 Mexico Market States and Outlook (2013-2023)
1.4.2 Europe (Germany, France, UK, Russia and Italy)
1.4.2.1 Germany Market States and Outlook (2013-2023)
1.4.2.2 France Market States and Outlook (2013-2023)
1.4.2.3 UK Market States and Outlook (2013-2023)
1.4.2.4 Russia Market States and Outlook (2013-2023)
1.4.2.5 Italy Market States and Outlook (2013-2023)
1.4.3 Asia-Pacific (China, Japan, Korea, India and Southeast Asia)
1.4.3.1 China Market States and Outlook (2013-2023)
1.4.3.2 Japan Market States and Outlook (2013-2023)
1.4.3.3 Korea Market States and Outlook (2013-2023)
1.4.3.4 India Market States and Outlook (2013-2023)
1.4.3.5 Southeast Asia Market States and Outlook (2013-2023)
1.4.4 South America, Middle East and Africa
1.4.4.1 Brazil Market States and Outlook (2013-2023)
1.4.4.2 Egypt Market States and Outlook (2013-2023)
1.4.4.3 Saudi Arabia Market States and Outlook (2013-2023)
1.4.4.4 South Africa Market States and Outlook (2013-2023)
1.4.4.5 Nigeria Market States and Outlook (2013-2023)
1.5 Market Dynamics
1.5.1 Market Opportunities
1.5.2 Market Risk
1.5.3 Market Driving Force
2 Manufacturers Profiles
2.1 Pharming Group NV
2.1.1 Business Overview
2.1.2 Hereditary Angioedema Type and Applications
2.1.2.1 Product A
2.1.2.2 Product B
2.1.3 Pharming Group NV Hereditary Angioedema Sales, Price, Revenue, Gross Margin and Market Share (2016-2017)
2.2 Shire plc
2.2.1 Business Overview
2.2.2 Hereditary Angioedema Type and Applications
2.2.2.1 Product A
2.2.2.2 Product B
2.2.3 Shire plc Hereditary Angioedema Sales, Price, Revenue, Gross Margin and Market Share (2016-2017)
2.3 CSL Limited
2.3.1 Business Overview
2.3.2 Hereditary Angioedema Type and Applications
2.3.2.1 Product A
2.3.2.2 Product B
2.3.3 CSL Limited Hereditary Angioedema Sales, Price, Revenue, Gross Margin and Market Share (2016-2017)
2.4 iBio Inc.
2.4.1 Business Overview
2.4.2 Hereditary Angioedema Type and Applications
2.4.2.1 Product A
2.4.2.2 Product B
2.4.3 iBio Inc. Hereditary Angioedema Sales, Price, Revenue, Gross Margin and Market Share (2016-2017)
2.5 BioCryst Pharmaceuticals, Inc.
2.5.1 Business Overview
2.5.2 Hereditary Angioedema Type and Applications
2.5.2.1 Product A
2.5.2.2 Product B
2.5.3 BioCryst Pharmaceuticals, Inc. Hereditary Angioedema Sales, Price, Revenue, Gross Margin and Market Share (2016-2017)
2.6 Ionis Pharmaceuticals, Inc.
2.6.1 Business Overview
2.6.2 Hereditary Angioedema Type and Applications
2.6.2.1 Product A
2.6.2.2 Product B
2.6.3 Ionis Pharmaceuticals, Inc. Hereditary Angioedema Sales, Price, Revenue, Gross Margin and Market Share (2016-2017)
3 Global Hereditary Angioedema Sales, Revenue, Market Share and Competition by Manufacturer (2016-2017)
3.1 Global Hereditary Angioedema Sales and Market Share by Manufacturer (2016-2017)
3.2 Global Hereditary Angioedema Revenue and Market Share by Manufacturer (2016-2017)
3.3 Market Concentration Rate
3.3.1 Top 3 Hereditary Angioedema Manufacturer Market Share in 2017
3.3.2 Top 6 Hereditary Angioedema Manufacturer Market Share in 2017
3.4 Market Competition Trend
4 Global Hereditary Angioedema Market Analysis by Regions
4.1 Global Hereditary Angioedema Sales, Revenue and Market Share by Regions
4.1.1 Global Hereditary Angioedema Sales and Market Share by Regions (2013-2018)
4.1.2 Global Hereditary Angioedema Revenue and Market Share by Regions (2013-2018)
4.2 North America Hereditary Angioedema Sales and Growth Rate (2013-2018)
4.3 Europe Hereditary Angioedema Sales and Growth Rate (2013-2018)
4.4 Asia-Pacific Hereditary Angioedema Sales and Growth Rate (2013-2018)
4.5 South America Hereditary Angioedema Sales and Growth Rate (2013-2018)
4.6 Middle East and Africa Hereditary Angioedema Sales and Growth Rate (2013-2018)
5 North America Hereditary Angioedema by Countries
5.1 North America Hereditary Angioedema Sales, Revenue and Market Share by Countries
5.1.1 North America Hereditary Angioedema Sales and Market Share by Countries (2013-2018)
5.1.2 North America Hereditary Angioedema Revenue and Market Share by Countries (2013-2018)
5.2 United States Hereditary Angioedema Sales and Growth Rate (2013-2018)
5.3 Canada Hereditary Angioedema Sales and Growth Rate (2013-2018)
5.4 Mexico Hereditary Angioedema Sales and Growth Rate (2013-2018)
6 Europe Hereditary Angioedema by Countries
6.1 Europe Hereditary Angioedema Sales, Revenue and Market Share by Countries
6.1.1 Europe Hereditary Angioedema Sales and Market Share by Countries (2013-2018)
6.1.2 Europe Hereditary Angioedema Revenue and Market Share by Countries (2013-2018)
6.2 Germany Hereditary Angioedema Sales and Growth Rate (2013-2018)
6.3 UK Hereditary Angioedema Sales and Growth Rate (2013-2018)
6.4 France Hereditary Angioedema Sales and Growth Rate (2013-2018)
6.5 Russia Hereditary Angioedema Sales and Growth Rate (2013-2018)
6.6 Italy Hereditary Angioedema Sales and Growth Rate (2013-2018)
7 Asia-Pacific Hereditary Angioedema by Countries
7.1 Asia-Pacific Hereditary Angioedema Sales, Revenue and Market Share by Countries
7.1.1 Asia-Pacific Hereditary Angioedema Sales and Market Share by Countries (2013-2018)
7.1.2 Asia-Pacific Hereditary Angioedema Revenue and Market Share by Countries (2013-2018)
7.2 China Hereditary Angioedema Sales and Growth Rate (2013-2018)
7.3 Japan Hereditary Angioedema Sales and Growth Rate (2013-2018)
7.4 Korea Hereditary Angioedema Sales and Growth Rate (2013-2018)
7.5 India Hereditary Angioedema Sales and Growth Rate (2013-2018)
7.6 Southeast Asia Hereditary Angioedema Sales and Growth Rate (2013-2018)
8 South America Hereditary Angioedema by Countries
8.1 South America Hereditary Angioedema Sales, Revenue and Market Share by Countries
8.1.1 South America Hereditary Angioedema Sales and Market Share by Countries (2013-2018)
8.1.2 South America Hereditary Angioedema Revenue and Market Share by Countries (2013-2018)
8.2 Brazil Hereditary Angioedema Sales and Growth Rate (2013-2018)
8.3 Argentina Hereditary Angioedema Sales and Growth Rate (2013-2018)
8.4 Colombia Hereditary Angioedema Sales and Growth Rate (2013-2018)
9 Middle East and Africa Hereditary Angioedema by Countries
9.1 Middle East and Africa Hereditary Angioedema Sales, Revenue and Market Share by Countries
9.1.1 Middle East and Africa Hereditary Angioedema Sales and Market Share by Countries (2013-2018)
9.1.2 Middle East and Africa Hereditary Angioedema Revenue and Market Share by Countries (2013-2018)
9.2 Saudi Arabia Hereditary Angioedema Sales and Growth Rate (2013-2018)
9.3 UAE Hereditary Angioedema Sales and Growth Rate (2013-2018)
9.4 Egypt Hereditary Angioedema Sales and Growth Rate (2013-2018)
9.5 Nigeria Hereditary Angioedema Sales and Growth Rate (2013-2018)
9.6 South Africa Hereditary Angioedema Sales and Growth Rate (2013-2018)
10 Global Hereditary Angioedema Market Segment by Type
10.1 Global Hereditary Angioedema Sales, Revenue and Market Share by Type (2013-2018)
10.1.1 Global Hereditary Angioedema Sales and Market Share by Type (2013-2018)
10.1.2 Global Hereditary Angioedema Revenue and Market Share by Type (2013-2018)
10.2 C1 Esterase Inhibitor Sales Growth and Price
10.2.1 Global C1 Esterase Inhibitor Sales Growth (2013-2018)
10.2.2 Global C1 Esterase Inhibitor Price (2013-2018)
10.3 Kallikrein Inhibitor Sales Growth and Price
10.3.1 Global Kallikrein Inhibitor Sales Growth (2013-2018)
10.3.2 Global Kallikrein Inhibitor Price (2013-2018)
10.4 Selective Bradykinin B2 Receptor Antagonist Sales Growth and Price
10.4.1 Global Selective Bradykinin B2 Receptor Antagonist Sales Growth (2013-2018)
10.4.2 Global Selective Bradykinin B2 Receptor Antagonist Price (2013-2018)
11 Global Hereditary Angioedema Market Segment by Application
11.1 Global Hereditary Angioedema Sales Market Share by Application (2013-2018)
11.2 Retail Pharmacies Sales Growth (2013-2018)
11.3 Hospital Pharmacies Sales Growth (2013-2018)
11.4 Online Pharmacies Sales Growth (2013-2018)
12 Hereditary Angioedema Market Forecast (2018-2023)
12.1 Global Hereditary Angioedema Sales, Revenue and Growth Rate (2018-2023)
12.2 Hereditary Angioedema Market Forecast by Regions (2018-2023)
12.2.1 North America Hereditary Angioedema Market Forecast (2018-2023)
12.2.2 Europe Hereditary Angioedema Market Forecast (2018-2023)
12.2.3 Asia-Pacific Hereditary Angioedema Market Forecast (2018-2023)
12.2.4 South America Hereditary Angioedema Market Forecast (2018-2023)
12.2.5 Middle East and Africa Hereditary Angioedema Market Forecast (2018-2023)
12.3 Hereditary Angioedema Market Forecast by Type (2018-2023)
12.3.1 Global Hereditary Angioedema Sales Forecast by Type (2018-2023)
12.3.2 Global Hereditary Angioedema Market Share Forecast by Type (2018-2023)
12.4 Hereditary Angioedema Market Forecast by Application (2018-2023)
12.4.1 Global Hereditary Angioedema Sales Forecast by Application (2018-2023)
12.4.2 Global Hereditary Angioedema Market Share Forecast by Application (2018-2023)
13 Sales Channel, Distributors, Traders and Dealers
13.1 Sales Channel
13.1.1 Direct Marketing
13.1.2 Indirect Marketing
13.1.3 Marketing Channel Future Trend
13.2 Distributors, Traders and Dealers
14 Research Findings and Conclusion
15 Appendix
15.1 Methodology
15.2 Data Source
List of Tables and Figures
Figure Hereditary Angioedema Picture
Table Product Specifications of Hereditary Angioedema
Figure Global Sales Market Share of Hereditary Angioedema by Types in 2017
ProactiveWe manage our resources 24/7 to identify issues and address them before they become problems
Quality & ReliabilityWe are committed to providing reliable and highly accurate data with an excellent quality control system
Global Outreach6 Major regions and 40+ countries level analysis accomplished
Competitive PricingOur pricing strategy is highly competitive in the market, without compensating on the quality and the timeline of project delivery
